Seeking Alpha

Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that...

Regeneron (REGN +9.4%) pops on a blowout Q1, posting a surprise profit on a revenue number that was easily 30% above consensus estimates. Total revenue doubled on record sales of Eyelea that came in at nearly twice consensus estimates. The company adds that the outperformance is likely to continue, and doubles its 2012 revenue expectations for the drug. Baird says the results were “bigger than our wildest expectations.”
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|